<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1039">
  <stage>Registered</stage>
  <submitdate>22/01/2006</submitdate>
  <approvaldate>22/01/2006</approvaldate>
  <nctid>NCT00280878</nctid>
  <trial_identification>
    <studytitle>Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma</studytitle>
    <scientifictitle>A Pilot Study of Rituximab in Combination With Out-patient Based VGF/F-GIV Salvage Therapies for Relapsed/Refractory CD20+ Lymphomas</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AH204/05</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-Hodgkin's Lymphoma (CD20+)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - gemcitabine
Treatment: drugs - vinorelbine
Treatment: drugs - ifosfamide
Treatment: drugs - rituximab

Treatment: drugs: gemcitabine


Treatment: drugs: vinorelbine


Treatment: drugs: ifosfamide


Treatment: drugs: rituximab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the safety of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF and/or F-GIV in combination with Rituximab.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine point estimates of the response rates achieved with R-VGF or R-F-GIV in previously treated patients with relapsed/refractory CD20+ B-cell NHL.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age &gt;18 years

          -  Relapsed or primary refractory CD20+ NHL

          -  ECOG 0 - 2

          -  Written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Intention to proceed with any form of transplant therapy following fewer than 2 cycles
             of protocol salvage therapy.

          -  Bilirubin &gt; 50Âµmol/litre unless secondary to lymphoma

          -  Creatinine &gt; 2 x upper limit of normal unless secondary to lymphoma

          -  Absolute neutrophil count &lt;0.5 x 109/litre and / or platelets &lt; 50 x 109/litre unless
             secondary to lymphoma

          -  Relapse within 6 months of a prior transplant procedure (autologous or allogeneic).

          -  Known sensitivity to E coli derived preparations</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Frankston Hospital - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Bayside Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase II pilot study evaluating the safety of a risk-adjusted outpatient-based
      approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim)
      and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim) in combination with
      Rituximab (R-VGF/R-F-GIV).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00280878</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Spencer, Assoc.Prof</name>
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>